| Title: |
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target. |
| Authors: |
Maich, William T.; Shaikh, Muhammad Vaseem; Puri, Anish; Rossotti, Martin A.; Grewal, Shan; Khanna, Aapti; Anand, Alisha; Mikolajewicz, Nicholas; Seyfrid, Mathieu P.; McKenna, Dillon A.; Subapanditha, Minomi; Mobilio, Daniel; Hussack, Greg; Sheff, Joey G.; Hill, Jennifer J.; Taleb, Mo; Kwiecien, Jacek M.; Salim, Sabra; Savage, Neil; Wang, Bill |
| Source: |
Science Translational Medicine; 5/13/2026, Vol. 18 Issue 849, p1-20, 20p |
| Subject Terms: |
Glioblastoma multiforme; Chimeric antigen receptors; Cytotoxic T cells; Cancer stem cells; Tumor microenvironment; Macrophages; Immunotherapy |
| Abstract: |
Glioblastoma (GBM) comprises nearly 15% of primary central nervous system (CNS) tumors and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists in GBM, leading to inefficacy of current treatments and the absence of meaningful improvements in frontline therapies in the past 20 years. Through multiomic analysis of patient-derived primary and recurrent GBM cell lines, we identified the urokinase plasminogen activator receptor (uPAR) as a protumorigenic marker of putative brain tumor–initiating cells and a potential therapeutic target. We found that genetic disruption of uPAR expression impaired protumorigenic characteristics in vitro and in vivo, highlighting its biological role in tumorigenesis. We then generated uPAR-specific chimeric antigen receptor (CAR) T cells, which demonstrated potent antitumor activity in recurrent GBM patient–derived xenograft models. In addition to direct tumor cell killing, we found that uPAR is expressed on GBM-associated macrophages, enabling uPAR CAR T cells to target both GBM itself and cells in the tumor microenvironment. Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM. Editor's summary: A major challenge with immunotherapies, including those for glioblastoma, is the limited number of tumor-specific targets for the immune system to focus on; other targets may be enriched on tumor cells, but they run the risk of on-target, off-tumor effects. Here, Maich et al. used a multiomic approach to identify urokinase plasminogen activator receptor (uPAR) as a protein that is highly expressed in glioblastoma, specifically on brain tumor–initiating cells. Deletion of uPAR impaired tumor growth in vitro and in vivo, suggesting that loss of this protein as an immune evasion strategy may come at a fitness cost. Last, the authors generated chimeric antigen receptor T cells specific for uPAR, showing that they not only killed tumor cells in murine models but could also deplete uPAR-expressing tumor-associated macrophages. Thus, this two-for-one approach both kills tumor cells and contributes to remodeling of the tumor microenvironment, making uPAR an attractive target for glioblastoma-directed immunotherapies. —Courtney Malo [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Science Translational Medicine is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |